1
Clinical Trials associated with Allogeneic anti-CD19 CAR-T (920th Hospital of Joint Logistics Support Force of People's Liberation Army of China)An Investigator-initiated Trial to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of Relapsed/Refractory(r/r) CD19+ B-cell Acute Lymphoblastic Leukemia(B-ALL)
This is a single-arm, single-center, open-labeled clinical study to evaluate the safety and efficacy of UCAR-T Cells injection for patients with relapsed/refractory(r/r) B-cell Acute Lymphoblastic Leukemia(B-ALL).
100 Clinical Results associated with Allogeneic anti-CD19 CAR-T (920th Hospital of Joint Logistics Support Force of People's Liberation Army of China)
100 Translational Medicine associated with Allogeneic anti-CD19 CAR-T (920th Hospital of Joint Logistics Support Force of People's Liberation Army of China)
100 Patents (Medical) associated with Allogeneic anti-CD19 CAR-T (920th Hospital of Joint Logistics Support Force of People's Liberation Army of China)
100 Deals associated with Allogeneic anti-CD19 CAR-T (920th Hospital of Joint Logistics Support Force of People's Liberation Army of China)